Trial Profile

A Randomized, Open-Label, Parallel-Group, Single-dose, Relative Bioavailability Study of the Pharmacokinetics of Subcutaneous Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process J Relative to the Current Abatacept Drug Process F in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary)
Indications Alopecia areata; Common variable immunodeficiency; COVID 2019 infections; Dermatomyositis; Diffuse scleroderma; Graft-versus-host disease; Interstitial lung diseases; Juvenile rheumatoid arthritis; Lupus nephritis; Myositis; Nephrotic syndrome; Polymyalgia rheumatica; Polymyositis; Psoriatic arthritis; Pulmonary sarcoidosis; Rheumatoid arthritis
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com